A 42-year-old woman with recurrent pancreatitis from severe high triglycerides was successfully treated with a GLP-1 receptor agonist — achieving 15% weight loss, sustained triglyceride reduction, and no further pancreatitis episodes despite the drug class being typically avoided in pancreatitis patients.
15% weight loss, zero pancreatitis recurrenceGLP-1RA achieved sustained triglyceride reduction in a patient with recurrent HTG-induced pancreatitis — despite the drug class being typically avoided in pancreatitis patients
What the researchers found
A 42-year-old woman with recurrent hypertriglyceridemia-induced acute pancreatitis was started on a GLP-1 receptor agonist despite the conventional concern about pancreatitis risk with this drug class. The outcomes were markedly positive:
- 15% body weight loss achieved
- Sustained triglyceride reduction maintained
- No recurrence of acute pancreatitis while on GLP-1RA therapy
This challenges the blanket avoidance of GLP-1RAs in patients with pancreatitis history and suggests that when severe hypertriglyceridemia is the root cause, the triglyceride-lowering benefit may outweigh the theoretical pancreatitis risk.
Why it matters
Severe hypertriglyceridemia causes about 10% of acute pancreatitis cases and tends to recur. Managing triglycerides in these patients is crucial but often difficult. GLP-1RAs are powerful triglyceride-lowering agents, but their package insert warns about pancreatitis, creating a therapeutic dilemma. This case suggests that for HTG-induced pancreatitis specifically, GLP-1RAs may actually prevent recurrence by addressing the root cause — a paradigm shift in how we think about the pancreatitis warning.
How the study worked
Single patient case report documenting the clinical course of a 42-year-old woman with recurrent hypertriglyceridemia-induced acute pancreatitis who was initiated on GLP-1RA therapy. Weight, triglyceride levels, and pancreatitis recurrence were monitored during treatment.
What this study cannot tell us
This is a single case report — the lowest level of clinical evidence. The positive outcome in one patient cannot be generalized to all patients with HTG-induced pancreatitis. Confounding factors (other medications, dietary changes, time) cannot be controlled for. The duration of follow-up is not specified in the abstract. A single case cannot definitively establish that GLP-1RAs are safe in pancreatitis patients; randomized trials would be needed.
How to read the evidence
This is a single case report, which provides the lowest level of clinical evidence. While compelling for hypothesis generation and challenging clinical assumptions, it cannot establish causation or generalize to broader populations. It should be viewed as a signal warranting further investigation.
When this study was published
Published in 2025, this is a very recent case report reflecting current clinical practice with GLP-1 receptor agonists and the evolving understanding of their pancreatitis risk profile.
The bigger picture
The relationship between GLP-1RAs and pancreatitis has been debated since these drugs were first introduced. Large-scale studies have generally not confirmed an increased pancreatitis risk, but the warning persists in prescribing information. This case adds to a growing body of evidence suggesting that GLP-1RAs may actually be beneficial in specific pancreatitis populations — particularly those with hypertriglyceridemia as the root cause. If confirmed in larger studies, this could remove a barrier to treatment for patients who currently can't access these drugs.
Questions still open
- Should the blanket pancreatitis warning for GLP-1RAs be reconsidered for patients whose pancreatitis is caused by hypertriglyceridemia?
- Would a prospective trial of GLP-1RAs in HTG-induced pancreatitis patients show consistent benefit?
- What is the mechanism by which GLP-1RAs reduce triglycerides sufficiently to prevent pancreatitis recurrence?
Common questions
Why are GLP-1 drugs normally avoided in patients who've had pancreatitis?
How could a drug with a pancreatitis warning actually prevent pancreatitis?
Read the original research
Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis.
ACG case reports journal, 12(11), e01890
Citation
Guralwar, Chinmay; Mitsuhashi, Shuji; Ashkar, Motaz; Chedid, Victor G. (2025). Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis.. ACG case reports journal, 12(11), e01890. https://doi.org/10.14309/crj.0000000000001890